Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years. After: Measure: Incidence of adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Adverse Events (AEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of serious adverse events observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported Serious Adverse Events (SAEs) Time frame: Baseline to End of study, up to 5 years Measure: Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM Description: Patient incidence of reported LVEF \<50% Time frame: Baseline to End of study, up to 5 years.
Primary completion date changed
Before: Mar 2028. After: Mar 2029.